The placebo effect in Parkinson's disease

[1]  H. Byerly.  Explaining and Exploiting Placebo Effects , 2015, Perspectives in biology and medicine.

[2]  A Jon Stoessl,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Placebos and the Placebo Effect the Placebo Effect in Neurological Disorders , 2022 .

[3]  M Schulzer,et al.  Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's Disease , 2001, Science.

[4]  S. Houle,et al.  Influence of l-dopa and pramipexole on striatal dopamine transporter in early PD , 2001, Neurology.

[5]  A. Hrõbjartsson,et al.  Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. , 2001, The New England journal of medicine.

[6]  J Q Trojanowski,et al.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease. , 2001, The New England journal of medicine.

[7]  M Schulzer,et al.  Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. , 2001, Annals of neurology.

[8]  J. M. Anderson,et al.  Emotional conversations in Parkinson’s disease , 2001, Neurology.

[9]  Thomas J. H. Chen,et al.  The Reward Deficiency Syndrome: A Biogenetic Model for the Diagnosis and Treatment of Impulsive, Addictive and Compulsive Behaviors , 2000, Journal of psychoactive drugs.

[10]  J. Horvitz.  Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events , 2000, Neuroscience.

[11]  S. Leurgans,et al.  Objective changes in motor function during placebo treatment in PD , 2000, Neurology.

[12]  J. Stewart,et al.  The role of dopamine in the nucleus accumbens in analgesia. , 1999, Life sciences.

[13]  C. Olanow,et al.  Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. , 1999, The New England journal of medicine.

[14]  J. Friedman,et al.  The placebo response in Parkinson's disease. Parkinson Study Group. , 1999, Clinical neuropharmacology.

[15]  F. Benedetti,et al.  Somatotopic Activation of Opioid Systems by Target-Directed Expectations of Analgesia , 1999, The Journal of Neuroscience.

[16]  H. Curran,et al.  Additional methadone increases craving for heroin: a double-blind, placebo-controlled study of chronic opiate users receiving methadone substitution treatment. , 1999, Addiction.

[17]  Anne Harrington,et al.  The Placebo Effect: An Interdisciplinary Exploration , 1999 .

[18]  P. Garris,et al.  Dissociation of dopamine release in the nucleus accumbens from intracranial self-stimulation , 1999, Nature.

[19]  M. Flaten,et al.  Drug-related information generates placebo and nocebo responses that modify the drug response. , 1999, Psychosomatic medicine.

[20]  F. Benedetti,et al.  Neuropharmacological Dissection of Placebo Analgesia: Expectation-Activated Opioid Systems versus Conditioning-Activated Specific Subsystems , 1999, The Journal of Neuroscience.

[21]  R. Przewłocki,et al.  Effects of repeated psychostimulant administration on the prodynorphin system activity and kappa opioid receptor density in the rat brain , 1998, Neuroscience.

[22]  W. Schultz.  Predictive reward signal of dopamine neurons. , 1998, Journal of neurophysiology.

[23]  John R. C Christensen,et al.  Regional and temporal differences in real-time dopamine efflux in the nucleus accumbens during free-choice novelty , 1997, Brain Research.

[24]  A. Malhotra,et al.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Comings,et al.  The D2 Dopamine Receptor Gene as a Determinant of Reward Deficiency Syndrome , 1996, Journal of the Royal Society of Medicine.

[26]  R. Adams,et al.  Principles of Neurology , 1996 .

[27]  E. Nestler,et al.  Molecular Neurobiology of Drug Addiction , 1994, Neuropsychopharmacology.

[28]  R A Deyo,et al.  The importance of placebo effects in pain treatment and research. , 1994, JAMA.

[29]  K. Berridge,et al.  The neural basis of drug craving: An incentive-sensitization theory of addiction , 1993, Brain Research Reviews.

[30]  V. Pickel,et al.  Dual ultrastructural localization of enkephalin and tyrosine hydroxylase immunoreactivity in the rat ventral tegmental area: multiple substrates for opiate-dopamine interactions , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[31]  J. Salamone,et al.  Paradoxical kinesia in parkinsonism is not caused by dopamine release. Studies in an animal model. , 1989, Archives of Neurology.

[32]  G. Di Chiara,et al.  Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[33]  E. Tolosa,et al.  Parkinson's disease with depression , 1986, Neurology.

[34]  C. Markham,et al.  Double‐blind trial of pergolide for Parkinson's disease , 1985, Neurology.

[35]  M. Zigmond,et al.  Environmental stimuli but not homeostatic challenges produce apparent increases in dopaminergic activity in the striatum: An analysis by in vivo voltammetry , 1983, Brain Research.

[36]  S. Reiss.  Pavlovian conditioning and human fear: An expectancy model , 1980 .

[37]  H. Brody.  Placebos and the Philosophy of Medicine: Clinical, Conceptual, and Ethical Issues , 1980 .

[38]  Ian Wickramasekera PhD.  A conditioned response model of the placebo effect , 1980, Biofeedback and self-regulation.

[39]  L. Chiodo,et al.  Reciprocal influences of activating and immobilizing stimuli on the activity of nigrostriatal dopamine neurons , 1979, Brain Research.

[40]  H. Fields,et al.  MECHANISM OF PLACEBO ANALGESIA , 1978, The Lancet.

[41]  J. Cooper,et al.  The Biochemical Basis of Neuropharmacology , 1975 .

[42]  R. Pihl,et al.  An experimental analysis of the placebo effect. , 1971, The Journal of clinical pharmacology and new drugs.

[43]  H. Beecher.  Surgery as placebo. A quantitative study of bias. , 1961, JAMA.

[44]  S. Wolf.  The pharmacology of placebos. , 1959, Pharmacological reviews.

[45]  H. Beecher,et al.  The powerful placebo. , 1955, Journal of the American Medical Association.

[46]  A. Leslie.  Ethics and practice of placebo therapy. , 1954, The American journal of medicine.

[47]  Floyd E. Bloom,et al.  The biochemical basis of neuropharmacology, 8th ed. , 2003 .

[48]  D. Comings,et al.  Reward deficiency syndrome: genetic aspects of behavioral disorders. , 2000, Progress in brain research.

[49]  Irving Kirsch,et al.  Specifying nonspecifics: Psychological mechanisms of placebo effects. , 1997 .

[50]  R. Wise,et al.  Brain dopamine and reward. , 1989, Annual review of psychology.

[51]  S. Cooper,et al.  The Neuropharmacological basis of reward , 1989 .

[52]  G. Schwartz,et al.  Placebo Theory, Research , and Mechanisms , 1985 .

[53]  A. Grünbaum.  Explication and Implications of the Placebo Concept , 1984 .